Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Barry S. Rodgers-Gray, John R. Fullarton, Xavier Carbonell-Estrany, Ian P. Keary, Jean-Éric Tarride & Bosco A. Paes. (2023) Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants. Journal of Medical Economics 26:1, pages 630-643.
Read now
Read now
Bosco Paes, John R. Fullarton, Barry S. Rodgers-Gray & Xavier Carbonell-Estrany. (2021) Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants. Current Medical Research and Opinion 37:7, pages 1149-1153.
Read now
Read now
Ashleigh A. McGirr, Kevin L. Schwartz, Upton Allen, Melinda Solomon & Beate Sander. (2017) The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model. Human Vaccines & Immunotherapeutics 13:3, pages 599-606.
Read now
Read now
Haben Y Abraha, Krista L Lanctôt & Bosco Paes. (2015) Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Review of Respiratory Medicine 9:6, pages 779-799.
Read now
Read now
Leonard B. Weiner, Anthony S. Masaquel, Mark J. Polak & Parthiv J. Mahadevia. (2012) Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. Journal of Medical Economics 15:5, pages 997-1018.
Read now
Read now
Julia M Hussman, Abby Li, Bosco Paes & Krista L Lanctôt. (2012) A review of cost–effectiveness of palivizumab for respiratory syncytial virus. Expert Review of Pharmacoeconomics & Outcomes Research 12:5, pages 553-567.
Read now
Read now
Kelly A. Smart, Bosco A. Paes & Krista L. Lanctôt. (2010) Changing costs and the impact on RSV prophylaxis. Journal of Medical Economics 13:4, pages 705-708.
Read now
Read now
Kelly A. Smart, Krista L. Lanctôt & Bosco A. Paes. (2010) The cost effectiveness of palivizumab: a systematic review of the evidence. Journal of Medical Economics 13:3, pages 453-463.
Read now
Read now
Michael L. Forbes, Caroline B. Hall, Anne Jackson, Anthony S. Masaquel & Parthiv J. Mahadevia. (2010) Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life. Journal of Medical Economics 13:1, pages 136-141.
Read now
Read now
Derrick Y. Tam, Anna Banerji, Bosco A. Paes, Charles Hui, Jean-Eric Tarride & Krista L. Lanctôt. (2009) The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. Journal of Medical Economics 12:4, pages 361-370.
Read now
Read now
Bosco Paes, Mara Cole, Andrew Latchman & Janet Pinelli. (2009) Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada. Current Medical Research and Opinion 25:9, pages 2191-2196.
Read now
Read now
Robinson Joan L.Lanctôt Krista L.Paes Bosco, Hui Charles, Chiu Aaron & Tarride Jean-Eric. (2009) Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis. Current Medical Research and Opinion 25:7, pages 1631-1633.
Read now
Read now
Bosco Paes, Susan Steele, Marianne Janes & Janet Pinelli. (2009) Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada. Current Medical Research and Opinion 25:7, pages 1585-1591.
Read now
Read now
Articles from other publishers (39)
Affan Shoukat, Elaheh Abdollahi, Alison P. Galvani, Scott A. Halperin, Joanne M. Langley & Seyed M. Moghadas. (2023) Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. The Lancet Regional Health - Americas 28, pages 100629.
Crossref
Crossref
Mary T. Caserta, Sean T. O’Leary, Flor M. Munoz, Shawn L. Ralston, Sean T. O’Leary, James D. Campbell, Monica I. Ardura, Ritu Banerjee, Kristina A. Bryant, Mary T. Caserta, Jeffrey S. Gerber, Chandy C. John, Athena P. Kourtis, Angela Myers, Pia Pannaraj, Adam J. Ratner, José R. Romero, Samir S. Shah, Kenneth M. Zangwill, Yvonne A. Maldonado, Flor M. Munoz, Shawn L. Ralston, David W. Kimberlin, Elizabeth D. Barnett, Ruth Lynfield, Mark H. Sawyer, Henry H. Bernstein, Karen M. Farizo, Lisa M. Kafer, David Kim, Eduardo López Medina, Denee Moore, Lakshmi Panagiotakopoulos, Laura Sauvé, Jeffrey R. Starke, Jennifer Thompson, Kay M. Tomashek, Melinda Wharton, Charles R. WoodsJr.Jr. & Jennifer M. Frantz. (2023) Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics.
Crossref
Crossref
Brian C. King, Meredith E. Mowitz & John A.F. Zupancic. (2021) The financial burden on families of infants requiring neonatal intensive care. Seminars in Perinatology 45:3, pages 151394.
Crossref
Crossref
Marianne Bracht, Fabiana Bacchini & Bosco Paes. (2021) A Survey of Parental Knowledge of Respiratory Syncytial Virus and Other Respiratory Infections in Preterm Infants. Neonatal Network 40:1, pages 14-24.
Crossref
Crossref
Jesse Papenburg, Mahwesh Saleem, Johannes Teselink, Abby Li, Georges Caouette, Édith MasséKrista L. Lanctôt. (2020) Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec. Pediatric Infectious Disease Journal 39:8, pages 694-699.
Crossref
Crossref
Bosco Paes, Barry Rodgers-Gray & Xavier Carbonell-Estrany. 2019. The Burden of Respiratory Syncytial Virus Infection in the Young. The Burden of Respiratory Syncytial Virus Infection in the Young.
Stephen MacAmanda SumnerSamuel Duchesne-BelangerRobert StirlingMatthew TunisBeate Sander. (2019) Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. Pediatrics 143:5.
Crossref
Crossref
Stavros Petrou. (2019) Health economic aspects of late preterm and early term birth. Seminars in Fetal and Neonatal Medicine 24:1, pages 18-26.
Crossref
Crossref
Gary M. Ginsberg, Eli Somekh & Yechiel Schlesinger. (2018) Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis. Israel Journal of Health Policy Research 7:1.
Crossref
Crossref
Maarten O. Blanken, Bosco Paes, Evan J. Anderson, Marcello Lanari, Margaret Sheridan-Pereira, Scot Buchan, John R. Fullarton, ElizaBeth Grubb, Gerard Notario, Barry S. Rodgers-Gray & Xavier Carbonell-Estrany. (2018) Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. Pediatric Pulmonology 53:5, pages 605-612.
Crossref
Crossref
Natalia Olchanski, Ryan N Hansen, Elle Pope, Brittany D’Cruz, Jaime Fergie, Mitchell Goldstein, Leonard R Krilov, Kimmie K McLaurin, Barbara Nabrit-Stephens, Gerald Oster, Kenneth Schaecher, Fadia T Shaya, Peter J Neumann & Sean D Sullivan. (2018) Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. Open Forum Infectious Diseases 5:3.
Crossref
Crossref
Evan J. Anderson, Xavier Carbonell-Estrany, Maarten Blanken, Marcello Lanari, Margaret Sheridan-Pereira, Barry Rodgers-Gray, John Fullarton, Elisabeth Rouffiac, Pamela Vo, Gerard Notario, Fiona Campbell & Bosco Paes. (2017) Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons. Pediatric Infectious Disease Journal 36:2, pages 160-167.
Crossref
Crossref
Ian Mitchell, Isabelle Defoy & ElizaBeth Grubb. (2017) Burden of Respiratory Syncytial Virus Hospitalizations in Canada. Canadian Respiratory Journal 2017, pages 1-9.
Crossref
Crossref
Margaret Sheridan-Pereira, Joan Murphy, Julie Sloan, Gloria Crispino, Anne Leahy, J. David Corcoran, Eugene Dempsey, Basil Elnazir, Patrick Gavin, Farhana Sharif, Rizwan Gul, Salius Satas, John Murphy, Siobhan Gormally, Issam Shanaa, David Waldron, Paul Mc Mahon, John Carson, Maarten Blanken, Louis Bont & Bosco Paes. (2016) Respiratory Syncytial Virus Preterm (32–36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland. Pediatric Infectious Disease Journal 35:1, pages 19-24.
Crossref
Crossref
Rafat Mosalli, Asmaa Mostafa Abdul Moez, Mohammed Janish & Bosco Paes. (2015) Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants. Journal of Medical Virology 87:8, pages 1285-1291.
Crossref
Crossref
Colleen Wegzyn, Lim Kai Toh, Gerard Notario, Sophie Biguenet, Kristina Unnebrink, Caroline Park, Doris Makari & Michael Norton. (2014) Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review. Infectious Diseases and Therapy 3:2, pages 133-158.
Crossref
Crossref
Michael T. Brady, Carrie L. Byington, H. Dele Davies, Kathryn M. Edwards, Mary Anne Jackson, Yvonne A. Maldonado, Dennis L. Murray, Walter A. Orenstein, Mobeen H. Rathore, Mark H. Sawyer, Gordon E. Schutze, Rodney E. Willoughby, Theoklis E. Zaoutis, Shawn L. Ralston, Allan S. Lieberthal, H. Cody Meissner, Brian K. Alverson, Jill E. Baley, Anne M. Gadomski, David W. Johnson, Michael J. Light, Nizar F. Maraqa, Eneida A. Mendonca, Kieran J. Phelan, Joseph J. Zorc, Danette Stanko-Lopp & Sinsi Hernández-Cancio. (2014) Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics 134:2, pages e620-e638.
Crossref
Crossref
J. Murray, S. Saxena & M. Sharland. (2014) Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. Archives of Disease in Childhood 99:5, pages 469-473.
Crossref
Crossref
Andrew HiattNatasha BohorovaOgnian BohorovCharles GoodmanDo KimMichael H. PaulyJesus VelascoKevin J. WhaleyPedro A. Piedra, Brian E. Gilbert & Larry Zeitlin. (2014) Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proceedings of the National Academy of Sciences 111:16, pages 5992-5997.
Crossref
Crossref
Andrea T. Borchers, Christopher Chang, M. Eric Gershwin & Laurel J. Gershwin. (2013) Respiratory Syncytial Virus—A Comprehensive Review. Clinical Reviews in Allergy & Immunology 45:3, pages 331-379.
Crossref
Crossref
Tea Andabaka, Jason W Nickerson, Maria Ximena Rojas-Reyes, Juan David Rueda, Vesna Bacic Vrca & Bruno Barsic. (2013) Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Evidence-Based Child Health: A Cochrane Review Journal 8:6, pages 2243-2376.
Crossref
Crossref
Stephane A. Régnier. (2013) Respiratory syncytial virus immunization program for the United States: Impact of performance determinants of a theoretical vaccine. Vaccine 31:40, pages 4347-4354.
Crossref
Crossref
Louis Bont & Maarten Blanken. (2013) Viral respiratory burden in moderate-to-late preterm infants. Early Human Development 89, pages S37-S39.
Crossref
Crossref
Tea Andabaka, Jason W Nickerson, Maria Ximena Rojas-Reyes, Juan David Rueda, Vesna Bacic Vrca & Bruno Barsic. (2013) Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Maarten O. Blanken, Hendrik Koffijberg, Elisabeth E. Nibbelke, Maroeska M. Rovers & Louis Bont. (2013) Prospective Validation of a Prognostic Model for Respiratory Syncytial Virus Bronchiolitis in Late Preterm Infants: A Multicenter Birth Cohort Study. PLoS ONE 8:3, pages e59161.
Crossref
Crossref
B. Paes, I. Mitchell, A. Li & K. L. Lanctôt. (2012) A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). European Journal of Clinical Microbiology & Infectious Diseases 31:10, pages 2703-2711.
Crossref
Crossref
Pooja Harijan & Elaine M. Boyle. (2012) Health outcomes in infancy and childhood of moderate and late preterm infants. Seminars in Fetal and Neonatal Medicine 17:3, pages 159-162.
Crossref
Crossref
P. Manzoni, B. Paes, B. Resch, A. Mejias, O. Ramilo, X. Carbonell-Estrany & L. Bont. (2012) High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Human Development 88, pages S34-S41.
Crossref
Crossref
B. Paes, I. Mitchell, A. Li & K.L. Lanctôt. (2011) Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. European Journal of Pediatrics 171:5, pages 833-841.
Crossref
Crossref
Marianne Bracht, Debbie Basevitz, Marilyn Cranis, Rose Paulley & Bosco Paes. (2012) Identifying and Ensuring Optimal Care for All Children at Risk of Developing Serious Respiratory Syncytial Virus Disease: A Canadian Nurses’ Perspective. Neonatal Network 31:6, pages 369-386.
Crossref
Crossref
Amanda Burls & Josie Sandercock. (2011) Decision-making under conditions of uncertainty-what can we learn from palivizumab?. Acta Paediatrica 100:10, pages 1302-1305.
Crossref
Crossref
Marianne Bracht, Debbie Basevitz, Marilyn Cranis & Rose Paulley. (2012) Impact of Respiratory Syncytial Virus. Drugs in R&D 11:3, pages 215-226.
Crossref
Crossref
Bosco Paes & Paolo Manzoni. (2011) Special populations: Do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis?. Early Human Development 87, pages S55-S58.
Crossref
Crossref
Bernhard Resch & Bosco Paes. (2011) Are late preterm infants as susceptible to RSV infection as full term infants?. Early Human Development 87, pages S47-S49.
Crossref
Crossref
Sung Ju MinJung Sook SongJang Hwan ChoiHan Su SeonEun Kyeong KangDo Hyun KimHee Sup Kim. (2011) Analysis of Palivizumab Prophylaxis in Patients with Acute Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus. Korean Journal of Pediatric Infectious Diseases 18:2, pages 154.
Crossref
Crossref
George A. Gregory & Claire Brett. 2011. Smith's Anesthesia for Infants and Children. Smith's Anesthesia for Infants and Children
512
553
.
Leonard R. Krilov, Debra L. Palazzi, Ancilla W. Fernandes, Robert W. Klein & Parthiv J. Mahadevia. (2010) Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United States. Value in Health 13:1, pages 77-86.
Crossref
Crossref
L Samson. (2009) La prévention de l'infection par le virus respiratoire syncytial. Paediatrics & Child Health 14:8, pages 527-532.
Crossref
Crossref
L Samson. (2009) Prevention of respiratory syncytial virus infection. Paediatrics & Child Health 14:8, pages 521-526.
Crossref
Crossref